Ikena Oncology
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-01-01
- Employees
- 43
- Market Cap
- $83.7M
- Website
- http://www.ikenaoncology.com
- Introduction
Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed and biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412, and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.
Clinical Trials
6
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
- Conditions
- Non-Small Cell Lung CarcinomaGliomas, MalignantSolid Tumor, AdultColorectal CancerPancreatic CancerMalignant MelanomaRas (Kras or Nras) Gene MutationCRAF Gene MutationThyroid CarcinomaBRAF Gene Mutation
- Interventions
- First Posted Date
- 2024-02-21
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Ikena Oncology
- Target Recruit Count
- 150
- Registration Number
- NCT06270082
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Johns Hopkins University of Medicine Sidney Kimmel Comprehensive Care Center, Washington, District of Columbia, United States
🇺🇸University of Miami, Miami, Florida, United States
Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer
- Conditions
- Head Cancer NeckNeck CancerHead and Neck CancerNeck CarcinomaHead and Neck Squamous Cell CarcinomaHead Cancer
- Interventions
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Ikena Oncology
- Registration Number
- NCT05472506
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Washington University, Saint Louis, Missouri, United States
🇺🇸UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
A Phase 1 study to evaluate IK-930 in subjects with advanced solid tumors
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Ikena Oncology Inc.
- Target Recruit Count
- 31
- Registration Number
- 2022-502622-40-00
- Locations
- 🇫🇷
Centre Leon Berard, Lyon, France
🇫🇷Institut Bergonie, Bordeaux, France
🇫🇷Centre Oscar Lambret, Lille, France
A Study of PY314 in Subjects With Advanced Solid Tumors
- Conditions
- Advanced Solid TumorTriple Negative Breast CancerLung AdenocarcinomaRenal Cell CarcinomaOvarian CancerGynecologic CancerBreast CancerColorectal CancerHormone Receptor/Growth Factor Receptor-Negative Breast Cancer
- Interventions
- First Posted Date
- 2020-12-31
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Ikena Oncology
- Target Recruit Count
- 86
- Registration Number
- NCT04691375
- Locations
- 🇺🇸
Mayo Clinic Scottsdale - PPDS, Phoenix, Arizona, United States
🇺🇸Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸City of Hope - Comprehensive Cancer Center, Duarte, California, United States
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
- Conditions
- Gastric AdenocarcinomaColorectal CancerPancreatic CancerAdvanced Solid TumorGynecologic CancerBreast CancerLung AdenocarcinomaHead and Neck Cancer
- Interventions
- Drug: PY159 Single agent dose level 4Drug: PY159 Single agent dose level 7Drug: PY159 Single agent dose level 2Drug: PY159 Single agent dose level 3Drug: PY159/Pembrolizumab Combination dose expansion cohort 6Drug: PY159 Single agent dose level 1Drug: PY159 Single agent dose expansion cohortDrug: PY159/Pembrolizumab Combination dose expansion cohort 2Drug: PY159/Pembrolizumab Combination dose expansion cohort 3Drug: PY159 Single agent dose level 5Drug: PY159 Single agent dose level 6Drug: PY159/Pembrolizumab Combination dose level 3Drug: PY159/Pembrolizumab Combination dose level 4Drug: PY159/Pembrolizumab Combination dose expansion cohort 1Drug: PY159/Pembrolizumab Combination dose expansion cohort 4Drug: PY159/Pembrolizumab Combination dose expansion cohort 5Drug: PY159/Pembrolizumab Combination dose level 1Drug: PY159/Pembrolizumab Combination dose level 2
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Ikena Oncology
- Target Recruit Count
- 127
- Registration Number
- NCT04682431
- Locations
- 🇺🇸
USC Norris Cancer Center, Los Angeles, California, United States
🇺🇸UCSF Mount Zion Cancer Center, San Francisco, California, United States
🇺🇸UCLA Parkside Cancer Center, Santa Monica, California, United States
- Prev
- 1
- 2
- Next
News
Former Poseida CEO Kristin Yarema Named to Lead Ikena-Inmagene Merger as Companies Advance Anti-OX40 Therapy
Ikena Oncology and Inmagene Biopharmaceuticals have appointed former Poseida Therapeutics CEO Kristin Yarema to lead the merged company ImageneBio following their anticipated July 2025 closing.
Hillstar Bio Strengthens Leadership Team with Key Appointments to Advance Precision Immunotherapy Pipeline
Hillstar Bio appointed Maude Tessier, Ph.D., as Chief Operating Officer and Shiva Krupa, Ph.D., MBA, as Vice President of Program Management to strengthen leadership capabilities.
Pharmaceutical Industry Faces Widespread Layoffs Amid Patent Cliffs and Economic Uncertainty
• Major pharmaceutical companies including Pfizer, Novartis, and Takeda have implemented significant workforce reductions over the past year due to patent cliffs and economic pressures. • Unlike previous trends, current layoffs are heavily impacting R&D departments, marking a shift from traditional commercial-focused cuts and reflecting the industry's evolving outsourcing landscape. • Contract Research Organizations (CROs) are benefiting from the industry shift, absorbing displaced talent and gaining additional business as pharmaceutical companies restructure their operations.